Compare Gold Fields Limited (GFI) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Travere Therapeutics Inc. Common Stock — how do they compare? Gold Fields Limited trades at $36.55 (market cap $32.04B), while Travere Therapeutics Inc. Common Stock trades at $53.44 (market cap $5.02B). The key difference: Gold Fields Limited is far larger — about 6.4× Travere Therapeutics Inc. Common Stock's market cap, and Gold Fields Limited pays a 6.06% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 50 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| GFI | TVTX | |
|---|---|---|
Market Cap | $32.04B | $5.02B |
Volume | 3,910,984 | 2,060,842 |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $67.52 |
52-Week Low | $31.25 | $26.79 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | $32.64B | $5.15B |
Dividend Yield | 6.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $36.34, down 1.14% amid bearish technical signals despite strong fundamentals. The stock shows robust profitability with 38.66% net margins and attractive valuation at 7.4x P/E. Recent earnings show mixed results with one beat and three misses, while news highlights the rejected $27 billion Northern Star takeover bid causing volatility. Cash flow remains healthy with $919 million net inflow in 2025.
GFI presents value opportunity with low valuations and strong cash generation, but faces execution risks from acquisition strategy and gold price sensitivity. Analyst consensus at $49.06 target suggests 35% upside, though technical weakness near support at $36 requires monitoring. The company's disciplined capital return program ($1.25 billion shareholder returns) supports bullish case.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
